GTx-104 continues to demonstrate clinical and delivery advantages over oral nimodipine. The upcoming AAN presentation may catalyze investor and KOL interest ahead of a potential NDA submission. Monitor for further regulatory updates and potential partnership interest.
Price Chart
Executive Summary
Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH), will be presented at the 2026 American Academy of Neurology meeting. The trial met its primary endpoint, showing a 19% relative reduction in clinically significant hypotension with GTx-104 versus oral nimodipine, along with better dose intensity and functional outcomes.
Key Facts
- STRIVE-ON trial met primary endpoint: 28% of GTx-104 patients experienced clinically significant hypotension vs. 35% on oral nimodipine (19% relative reduction).
- 54% of GTx-104 patients achieved ≥95% relative dose intensity vs. 8% on oral nimodipine.
- 29% more patients on GTx-104 had favorable functional outcomes at 90 days compared to oral nimodipine.
- No new safety signals were identified; all deaths were attributed to underlying disease severity, not treatment.
- Data to be presented April 21, 2026, at AAN meeting, a key medical forum for neurology stakeholders.
Financial Impact
Potential for improved pharmacoeconomic profile with fewer ICU readmissions, ventilator days, and ICU days, though exact dollar impact not quantified.
Risk Factors
- Regulatory approval not guaranteed despite positive Phase 3 data.
- Higher mortality in GTx-104 arm (8 vs. 4 deaths) could raise questions, though deemed unrelated to treatment.
- Market cap remains small ($51M), making stock volatile to sentiment shifts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273250 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers